Mesenchymal Stem Cell Therapy for Bone Repair of Human Hip Osteonecrosis with Bilateral Match-Control Evaluation: Impact of Tissue Source, Cell Count, Disease Stage, and Volume Size on 908 Hips
Cells · 2024
DOI: 10.3390/cells13090776 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2024. Verfasst von Philippe Hernigou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Orthopedic Department, University Paris East, Hopital Henri Mondor, 94000 Creteil, France. Hauptthemen laut MEDLINE: Mesenchymal Stem Cell Transplantation, Femur Head Necrosis. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Research Council under the European Union’s Seventh Framework Programme, REBORNE Project, Agence Nationale pour la Recherche.
Abstract (Originalsprache)
We investigated the impact of mesenchymal stem cell (MSC) therapy on treating bilateral human hip osteonecrosis, analyzing 908 cases. This study assesses factors such as tissue source and cell count, comparing core decompression with various cell therapies. This research emphasizes bone repair according to pre-treatment conditions and the specificities of cell therapy in osteonecrosis repair, indicating a potential for improved bone repair strategies in hips without femoral head collapse. This study utilized a single-center retrospective analysis to investigate the efficacy of cellular approaches in the bone repair of osteonecrosis. It examined the impact on bone repair of tissue source (autologous bone marrow concentrate, allogeneic expanded, autologous expanded), cell quantity (from none in core decompression alone to millions in cell therapy), and osteonecrosis stage and volume. Excluding hips with femoral head collapse, it focused on patients who had bilateral hip osteonecrosis, both pre-operative and post-operative MRIs, and a follow-up of over five years. The analysis divided these patients into seven groups based on match control treatment variations in bilateral hip osteonecrosis, primarily investigating the outcomes between core decompression, washing effect, and different tissue sources of MSCs. Younger patients (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Orthopedic Department, University Paris East, Hopital Henri Mondor, 94000 Creteil, France.
- Department of Orthopaedics, Faculty of Medicine, Juntendo University, Bunkyo-ku, Tokyo 113-8421, Japan.
- Department of Orthopaedic Surgery and Traumatology, EpiCURA Baudour Hornu Ath Hospital, 7331 Hainaut, Belgium.
- Établissement Français du Sang, University Paris East, 94000 Creteil, France.
- AO Research Institute Davos, Clavadelerstrasse 8, 7270 Davos, Switzerland.
ORCID-Profile: Charles Henri Flouzat Lachaniette, Sophie Verrier
Förderung
- European Research Council under the European Union’s Seventh Framework Programme
- REBORNE Project
- Agence Nationale pour la Recherche
Zitieren
APA
Hernigou, P., Homma, Y., Hernigou, J., Flouzat Lachaniette, C. H., Rouard, H., & Verrier, S. (2024). Mesenchymal Stem Cell Therapy for Bone Repair of Human Hip Osteonecrosis with Bilateral Match-Control Evaluation: Impact of Tissue Source, Cell Count, Disease Stage, and Volume Size on 908 Hips. Cells. https://doi.org/10.3390/cells13090776
Vancouver
Hernigou P, Homma Y, Hernigou J, Flouzat Lachaniette CH, Rouard H, Verrier S. Mesenchymal Stem Cell Therapy for Bone Repair of Human Hip Osteonecrosis with Bilateral Match-Control Evaluation: Impact of Tissue Source, Cell Count, Disease Stage, and Volume Size on 908 Hips. Cells. 2024. doi:10.3390/cells13090776
BibTeX
@article{Hernigou2024,
author = {Hernigou, Philippe and Homma, Yasuhiro and Hernigou, Jacques and Flouzat Lachaniette, Charles Henri and Rouard, Helène and Verrier, Sophie},
title = {Mesenchymal Stem Cell Therapy for Bone Repair of Human Hip Osteonecrosis with Bilateral Match-Control Evaluation: Impact of Tissue Source, Cell Count, Disease Stage, and Volume Size on 908 Hips},
journal = {Cells},
year = {2024},
doi = {10.3390/cells13090776}
}
EUVIMED